A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study - Abou-Alfa, G K; Chan, S L; Furuse, J (J Clin Oncol, 2018)